

# **Supplementary Information**

## **Two Color Single Molecule Sequencing on GenoCare<sup>TM</sup> 1600**

### **Platform to Facilitate Clinical Applications**

Fang Chen, Bin Liu, Meirong Chen, Zefei Jiang, Zhiliang Zhou, Ping Wu, Meng Zhang, Huan Jin, Linsen Li, Liuyan Lu, Qi Wang, Huan Shang, Bing Xie, Lei Liu, Xia Lin, Weiyue Chen, Jianfeng Xu, Ruitao Sun, Guangming Wang, Jiao Zheng, Jifang Qi, Bo Yang, Dexia Chen, Lidong Zeng, Gailing Li, Yan Li, Hui Lv, Nannan Zhao, Bo Zhou, Wen Wang, Jinsen Cai, Siyu Liu, Weiwei Luo, Juan Zhang, Yanhua Zhang, Yongyi Lu, Jicai Fan, Haitao Dan, Xuesen He, Lichun Liu, Yan Feng, Jianglin Chen, Wei Huang, Lei Sun\*, Qin Yan\*.

Address: GeneMind Biosciences Company Limited, Build 2-602, No.116 Qingshuihe 1st Rd, Luohu District, Shenzhen, China, 518024


\* Corresponding author:

[sunlei@genemind.com](mailto:sunlei@genemind.com)

[yanqin@genemind.com](mailto:yanqin@genemind.com)

## Supplementary Information 1:


Each terminator shows different fluorescence intensity according to dye-labeled-nucleotides' structure and optical property. In sequencing, the average intensity and background show consistently fluctuations as the terminator combinations switch every cycle. On the other hand, the SNR shows similar pattern and slightly increase in later cycle (**Supplementary Figure 1**). Those phenomenon is the results of less background scattering caused by decreasing fluorescence signal density over time.



Supplementary Figure 1. (A) Normalized fluorescence intensity and background at 552nm and 664nm change in 70 cycle sequencing. (B) SNR in 70 cycles sequencing.

## **Supplementary Information 2:**


We hybridized and sequenced Phix 174 in a 16-lane flow cell using 72 cycles. The unique reads of each lane have been shown below (**Supplementary Figure 2**):



Supplementary Figure 2. Unique mapped reads of phix174 samples in 16 lanes.

### Supplementary Information 3:

Libraries of RNA samples from throat swabs are prepared using Tn5 transposome methods (**Supplementary Figure 3**). After reverse transcription, Tn5 transposome can randomly bind RNA/DNA heteroduplex and add sequencing adaptors. The complete libraries are obtained by PCR.



Supplementary Figure 3. Library preparation process for SARS-CoV-2 sample using transposase method.

#### **Supplementary Information 4:**

We used Sanger sequencing to confirm detected mutations on GenoCare™ 1600. The results are shown below:


#### **1022T samples:**

**Position: 28688**

**1&6-1 ref**

CTGGACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCT**T**GAATAAC  
ACCAAAAGATCACATTGGCACCCGCAATCCTGCTAACAAATGCTGCAATCGTGCTACAACCTCCTCAAG  
GAACAAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGGCGGCAGTCAAGCCTTTCTCGTT  
CCTCATCACGTAGTCGCAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACCTTCCTGCT  
AGAATGGCTGGCAATGGCGGTGATGCTGCTCTTGCTGCTGCTTGACAGATTGAACCAGCTTG  
AG

**Reverse sequencing result:**




**Position: 1397**

**2-2 ref**

TCTGTCTATCCAGTTGCGTCACCAAATGAATGCAACCAAATGTGCCTTCAACTCTCATGAAGTGTGA  
TCATTGTGGTGAACCTTCATGGCAGACGGCGATTTGTTAAAGCCACTTGCAGATTGTGGCACT  
GAGAATTGACTAAAGAAGGTGCCACTACTTGTGGTTACTTaCCCCAAATGCTGTTAAAATTAA  
TTGTCCAGCATGTCACAATTCAAGAAgTAGGACCTGAGCATAGTCTTGCAGAATACCATAATGAAT

**Forward sequencing result:**




**Position: 29742**

**3&5-1 ref**

ATTCTCGTAACTACATAGCACAAGTAGATGTTACTCACATAGCAATCTTAAATCAGTG  
TGTAACATTAGGGAGGGACTGAAAGAGCCACCACATTTCACCGAGGCCACgCGGAGTACGATCGA  
GTGTACAGTGAACAATGCTaGGGAGAGCTGCCTATATGGAAGAGCCCTAATGTGTAAAATTAATTT  
AGTAGTGCTATCCCCATGTGATTTA

**Forward sequencing result:**




**Position: 11083**

**4 ref**

AAGAACAAATCAAGGGTACACACCACTGGTTACTCACAATTTGACTTCAC

TTAGTTAGTCCA  
GAGTACTCAATGGTCTTGTCTTTTTTgTATGAAAATGCCTTTACCTTGCTATGGGTATTATT  
GCTATGTCGCTTGCAATGATGTTGTCAAACATAAGCATGCATTCTCTGTTGTTTGTACCTT  
CTCTGCCACTGTAGCTTATTTAATATGGTCTATATGCCTGCTAG

**Reverse sequencing result:**




**Position: 29776**

**3&5-2 ref**

ATTCTCGTAACTACATAGCACACAAGTAGATGTAGTTAACCTTAATCTCACATAGCAATCTTAAATCAGTG  
 TGTAACATTAGGGAGGACTTGAAAGAGCCACCACATTTCACCGAGGCCACgCGGAGTACGATCGA  
 GTGTACAGTGAACAATGCTaGGGAGAGCTGCCTATATGGAAGAGCCCTAATGTGAAAATTAATTTT  
AGTAGTGCTATCCCCATGTGATTTA

### Forward sequencing result:




### 1028T samples:

**Position: 8782**

**7 ref**

TGAAATCATAGGATACAAGGCTATTGATGGTGGTGTCACTCGTGACATAGCATCTACAGATACTGTT  
 TTGCTAACAAACATGCTGATTTGACACATGGTTAGcCAGCGTGGTGGTAGTTACTAATGACAAA  
 GCTTGCCCATTGATTGCTGCAGTCATAACAAGAGAAGTGGGTTGTCGTGCCTGGTTGCCTGGCA  
CGATATTACGCACAACTAATGGTGA

### Reverse sequencing result:




**Position: 28878**

**1&6-2 ref**

CTGGACTTCCCTATGGTGCTAACAAAGACGGCATCATATGGGTTGCAACTGAGGGAGCCTGAATAC  
 ACCAAAAGATCACATTGGCACCCGCAATCCTGCTAACAAATGCTGCAATCGTGCTACAACCTCCTCAAG  
 GAACAAACATTGCCAAAAGGCTCTACGCAGAAGGGAGCAGAGGCAGTCAGCCTTTCTCGTT

CCTCATCACGTAGTCGAAACAGTTCAAGAAATTCAACTCCAGGCAGCAGTAGGGGAACCTCTCCTGCT  
 AGAATGGCTGGCAATGGCGGTGATGCTGCTCTGCTTGCTGCTGCTGACAGATTGAACCAGCTT  
AG

**Forward sequencing result:**




**Position: 28144**

**8-2 ref**

TGACCCGTGTCCTATTCACTTCTATTCTAAATGGTAtATTAGAGTAGGAGCTAGAAAATCAGCACCTT  
 AATTGAATTGTGCGTGGATGAGGCTGGTCTAAATCACCCATTCACTACATCGATATCGGTAAATTATA  
CAGTTCCCTGTTtACCTTTACAATTAAATTGCCAGGAACCTAAATTGGGTAGTCTGTAGTGC

**Forward sequencing result:**




**Position: 8937**

**9 ref**

ATTACGCACAACTAATGGTGACTTTGCATTCTTACCTAGAGTTTAGTGcAGTTGGTAACATCTG  
 TTACACACCATCAAAACTTATAGAGTACACTGACTTGCACATCAGCTTGTGTTGGCTGCTGAAT  
 GTACAATTAAAGATGCTCTGGTAAGCCAGTACCATATTGTTATGATAACCAATGTACTAGAAGGT  
TCTGTTGCTTATGAAAGTTACGCC

**Reverse sequencing result:**



**Position: 29742**

**3&5-1 ref**

ATTCTCGTAACTACATAGCACAAGTAGATGTAGTTAACTTAATCTCACATAGCAATCTTAAATCAGTG  
 TGTAACATTAGGGAGGGACTTGAAAGAGCCACCACATTTCACCGAGGCCACgCGGAGTACGATCGA  
 GTGTACAGTGAACAATGCTaGGGAGAGCTGCCTATATGGAAGAGGCCCTAATGTGTAAAATTAATTT  
AGTAGTGCTATCCCCATGTGATTTA

**Forward sequencing result:**

